PTC THERAPEUTICS, INC. (PTCT) FY2025 10-K Annual Report
PTC THERAPEUTICS, INC. (PTCT) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
PTC THERAPEUTICS, INC. FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of treatments for rare diseases, with focus on sepiapterin programs from Censa acquisition
- • Strategic shift: Rights Satisfaction Agreement canceled contingent net sales payments, replaced with upfront $225.1M cash payment plus up to $500M milestone payments
Management Discussion & Analysis
- • Revenue impact: upfront $1.0B from Novartis Agreement in Jan 2025, with potential $1.9B milestones, 40% US profits share, tiered double-digit royalties ex-US
- • Operating cash flow $711.2M in 2025 vs $(107.7)M in 2024 and $(158.4)M in 2023, driven by Novartis upfront and clinical/commercial spend
Risk Factors
- • Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026
- • Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks
PTC THERAPEUTICS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$1.7B
▲ +114.5% YoY
Net Income
$683M
▲ +287.9% YoY
Operating Margin
50.1%
▲ +8760bp YoY
Net Margin
39.4%
▲ +8447bp YoY
ROE
-332.5%
▼ -36557bp YoY
Total Assets
$2.9B
▲ +70.0% YoY
EPS (Diluted)
$7.78
▲ +264.5% YoY
Operating Cash Flow
$711M
▲ +760.4% YoY
Source: XBRL data from PTC THERAPEUTICS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on PTC THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.